Access cutting-edge schizophrenia treatment through this clinical trial at a research site in Little Rock. Study-provided care at no cost to qualified participants.
Access schizophrenia specialists in Little Rock at no cost
This study follows strict safety protocols and ethical guidelines
All study-related schizophrenia treatment provided free
ML-007C-MA-211 is a Phase 2, randomized, double-blind, placebo-controlled study to evaluate the efficacy, safety, and tolerability of orally administered ML-007C-MA in inpatient adult participants aged 18 to 64 years with schizophrenia experiencing an acute exacerbation of psychosis. The primary objective is to evaluate the efficacy of ML-007C-MA compared with placebo in the treatment of subjects with inadequately controlled symptoms of schizophrenia as measured by the Positive and Negative Syn
Sponsor: MapLight Therapeutics
Check if you qualify for this schizophrenia clinical trial in Little Rock, AR
If you're searching for schizophrenia treatment options in Little Rock, AR, this clinical trial may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our Little Rock research site is actively enrolling participants for this clinical trial. You'll receive care from experienced schizophrenia specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.